Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib

Abstract

Modern therapy for rheumatoid arthritis (RA) allows not only to reduce the activity of immune-mediated inflammation and slow down the progression of the disease, but also to quickly eliminate the main symptoms that cause the most concern to patients, such as pain, functional disorders, fatigue. This action has an inhibitor of Janus kinases 1/ 2 – baricitinib, which quickly reduces the activity of inflammation, provides remission in RA, and has a high analgesic effect. The review discusses the role of autoimmune inflammation and the intracellular signaling pathway JAK/STAT (Janus kinase/signal transducers and activators of transcription) in the pathogenesis of chronic pain in RA, the role of baricitinib for effective control of pain intensity and fatigue.